4//SEC Filing
Foresite Capital Fund IV, L.P. 4
Accession 0001104659-24-044187
CIK 0001797768other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 2:15 PM ET
Size
20.4 KB
Accession
0001104659-24-044187
Insider Transaction Report
Form 4
Foresite Capital Management IV, LLC
10% Owner
Transactions
- Disposition to Issuer
Common Stock
2024-04-03−9,671,643→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2024-04-03−3,525,957→ 0 total(indirect: See Footnote) - Disposition to Issuer
Common Stock
2024-04-03−520,711→ 0 total(indirect: See Footnote)
Footnotes (4)
- [F1]Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share.
- [F2]The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
- [F3]The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
- [F4]The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Documents
Issuer
Kinnate Biopharma Inc.
CIK 0001797768
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001704131
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 2:15 PM ET
- Size
- 20.4 KB